PHARMACEUTICALS
Our Pharmaceuticals segment focuses on meeting important patient needs. With sales of $22.4 billion, we saw rapid growth of recently launched products. For the year, the segment experienced an operational sales decline of 1 percent. Excluding the impact of generic competition and health care reform, pharmaceutical sales would have increased by nearly 4 percent operationally.
We continued to make significant investments to expand our presence in emerging markets which grew at double-digit rates, as well as in new therapeutic areas like vaccines and Alzheimer’s disease. We are the leader in the U.S. immunology market, with three significant brands. Our flagship product REMICADE® (infliximab), for the treatment of a number of immune-mediated inflammatory diseases, grew 7 percent operationally. Newer products STELARA® (ustekinumab) and SIMPONI® (golimumab) continued increasing market share and generated more than a combined $600 million in sales for the year. REMICADE®, STELARA® and SIMPONI® contributed to 17 percent operational growth for the Immunology franchise.
In long-acting antipsychotics, we grew 14 percent operationally. RISPERDAL® CONSTA® (risperidone) Long-Acting Injection, an atypical antipsychotic administered every two weeks for the treatment of schizophrenia or the maintenance of bipolar 1 disorder, grew 6 percent operationally. INVEGA® SUSTENNA® (paliperidone palmitate), for the treatment of schizophrenia, continued to increase U.S. market share, contributing to our expanding market leadership.
In the HIV area, PREZISTA® (darunavir) and INTELENCE® (etravirine) grew sales operationally by 46 percent and 41 percent, respectively, achieving together more than $1 billion in sales for the first time while providing access to markets with the most significant need.
In Oncology, Velcade* (bortezomib), for multiple myeloma, grew 16 percent operationally while eclipsing $1 billion in sales outside the U.S. for the first time.
In addition, we continue to pursue line extensions. We submitted applications for several major line extensions, among them REMICADE® and SIMPONI®, which continue to build the strength of our Immunology franchise.
Over the next three years, we expect to file compounds to address critical medical needs, including Alzheimer’s disease and diabetes, conditions growing in prevalence as the population ages. With five compounds currently in registration and several more planned in the coming years, our portfolio ranks among the leaders in the industry. Our pipeline meets unmet needs and features many true innovations designed to change the treatment paradigm for patients.
* Velcade is a trademark of Millennium Pharmaceuticals, Inc.
